Mechanism of Action: Cytochrome P450 11B1 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Cytochrome P450 11B1 Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 11,278,547 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 11,020,393 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 11,478,471 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 10,835,530 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 10,517,868 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Strongbridge | RECORLEV | levoketoconazole | TABLET;ORAL | 214133-001 | Dec 30, 2021 | RX | Yes | Yes | 10,098,877 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
